EN · OpenOnco · DIS-CERVICAL — Auto-stub (88% наповненість)
← Back to galleryFeedback on this caseUA
OpenOnco · Treatment Plan
Treatment plan — DIS-CERVICAL
PLAN-AUTO-CERVICAL-001-V1 · v1 · 2026-04-27
Patient
AUTO-CERVICAL-001 · Algorithm: ALGO-CERVICAL-LOCALLY-ADVANCED-1L

Etiological driver

Etiological driver · etiologically_driven archetype
Карцинома шийки матки
  • High-risk HPV chronic infection (genotypes 16, 18, 31, 33, 45, 52, 58 — accounts for >99% of cases)
  • HIV co-infection (immunosuppression accelerates progression)
  • Smoking (cofactor for SCC)
  • Long-term oral contraceptives (modest cofactor for adenocarcinoma)
  • Multiple sexual partners + early coitarche (HPV transmission risk)

Clinical significance of mutations (ESCAT / OncoKB)

Tumor-board context — the engine does not use these tiers to rank tracks
BiomarkerVariantESCATOncoKBClinical significanceDrugsSources
No clinically actionable variants matched in this profile.

Treatment options (1 tracks)

Standard plan
★ DEFAULT
Indication
IND-CERVICAL-LOCALLY-ADVANCED-CRT
Regimen
Cisplatin radiosensitization (concurrent with EBRT + brachytherapy)
Drugs + NSZU
  • Cisplatin (DRUG-CISPLATIN) 40 mg/m² (cap 70 mg) · IV weekly × 5-6 doses concurrent with EBRT · IV ✓ NSZU covered
Reason
Engine default per algorithm ALGO-CERVICAL-LOCALLY-ADVANCED-1L: {'step': 1, 'outcome': False, 'branch': {'result': 'IND-CERVICAL-LOCALLY-ADVANCED-CRT'}, 'fired_red_flags': [], 'winner_red_flag': None}

Red flags — PRO / CONTRA aggressive

PRO-AGGRESSIVE

Triggers that push toward the aggressive track
  • Hydronephrosis or pelvic-mass-induced ureteric obstruction in cervical cancer (FIGO IIIB by definition). Mandates urgent renal decompression (percutaneous nephrostomy or ureteric stent) BEFORE cisplatin-based CRT — cisplatin nephrotoxic + ureteric obstruction worsens AKI. RF-CERVICAL-HYDRONEPHROSIS-PELVIC-OBSTRUCTION

CONTRA-AGGRESSIVE

Hard contraindications to escalation
  • —

What NOT to do

Explicit prohibitive rules, each grounded in a regimen / supportive care / contraindication entity
Standard plan (IND-CERVICAL-LOCALLY-ADVANCED-CRT)
  • Do NOT defer brachytherapy — completing CRT in <8 weeks essential for outcomes
  • Do NOT initiate cisplatin without resolving hydronephrosis if present
  • Do NOT skip HIV testing — co-infection alters prognosis + needs ART optimization

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Cisplatin radiosensitization (
7-day cycles × 5-6 weekly doses (~6 weeks of CRT)

MDT brief

Data quality

  • Unevaluated RedFlags: RF-CERVICAL-FRAILTY-AGE, RF-CERVICAL-HIGH-RISK-BIOLOGY, RF-CERVICAL-HYDRONEPHROSIS-PELVIC-OBSTRUCTION, RF-CERVICAL-INFECTION-SCREENING, RF-CERVICAL-PDL1-CPS-1-PLUS, RF-CERVICAL-TRANSFORMATION-PROGRESSION

Skill catalog (0/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
Specialistskill_idVersionLast reviewedSign-offsDomain
Specialist з клітинної терапії (CAR-T)cellular_therapy_specialistv0.1.02026-04-250cellular_therapy
Клінічний фармацевтclinical_pharmacistv0.1.02026-04-250clinical_pharmacy
Гематолог / онкогематологhematologistv0.1.02026-04-250hematology_oncology
Гематопатолог (специфічно для лімфом / лейкозів / мієломи)hematopathologistv0.1.02026-04-250hematopathology
Інфекціоніст / гепатологinfectious_disease_hepatologyv0.1.02026-04-250infectious_diseases
Медичний онколог (хіміотерапевт солідних пухлин)medical_oncologistv0.1.02026-04-250solid_oncology
Молекулярний генетик / молекулярний онкологmolecular_geneticistv0.1.02026-04-250molecular_oncology
Паліативна допомогаpalliative_carev0.1.02026-04-250palliative_care
Патолог (загальний)pathologistv0.1.02026-04-250pathology
Сімейний лікар / терапевтprimary_carev0.1.02026-04-250primary_care
Психолог / онкопсихологpsychologistv0.1.02026-04-250psychosocial
Радіотерапевт (променева терапія)radiation_oncologistv0.1.02026-04-250radiation_oncology
Лікар-радіологradiologistv0.1.02026-04-250diagnostic_imaging
Соціальний працівник / кейс-менеджерsocial_worker_case_managerv0.1.02026-04-250psychosocial
Хірург-онкологsurgical_oncologistv0.1.02026-04-250surgical_oncology
Specialist з трансплантації (BMT)transplant_specialistv0.1.02026-04-250cellular_therapy

Sources cited

Експериментальні опції (клінічні дослідження)

Третій трек плану — open-enrollment trials з ClinicalTrials.gov. Останнє оновлення: 2026-04-26. Render-time metadata; engine selection не змінюється цим блоком (CHARTER §8.3).
NCTNamePhaseСтатусСпонсорUAВключення (фрагмент)
NCT06778863A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPHASE1RECRUITINGClasp Therapeutics, Inc.—
NCT07104149Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical CancerPHASE2RECRUITINGThe First Affiliated Hospital of Zhengzhou University—
NCT04989647Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant RadiotherapyPHASE3RECRUITINGThe Central and Eastern European Gynecologic Oncology Group—
NCT05606133Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic CancersNARECRUITINGNorthwell Health—
NCT07178847cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell CarcinomasNARECRUITINGCentre Jean Perrin—
NCT03907826PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsPHASE3RECRUITINGSun Yat-sen University—
NCT03382158International PPB/DICER1 RegistryN/ARECRUITINGChildren's Hospitals and Clinics of Minnesota—
NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1 / PHASE2RECRUITINGPMV Pharmaceuticals, Inc—
NCT06215950A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerPHASE1RECRUITINGChongqing Precision Biotech Co., Ltd—
NCT02838836Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid CancersN/ARECRUITINGUniversity of Missouri-Columbia—

Перевіряти статус набору безпосередньо у дослідницькому центрі. Дані ctgov можуть відставати від поточного статусу UA-сайтів.

Доступність опцій в Україні

Per-track UA registration · НСЗУ · cost · access pathway. Render-time metadata; engine selection не залежить від цих полів (CHARTER §8.3).
ОпціяРеєстрація UAНСЗУCost orientationAccess pathway
Standard plan
Cisplatin radiosensitization (concurrent with EBRT + brachytherapy) (REG-CISPLATIN-RADIOSENS)
✓ зареєстровано✓ покривається₴-? — verify pathwayНСЗУ formulary
Trial · NCT06778863
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07104149
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04989647
Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT05606133
Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT07178847
cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT03907826
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT03382158
International PPB/DICER1 Registry
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06215950
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT02838836
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor

Інформація про ціни — orientation. Перевіряти у конкретній аптеці / foundation / трайл-сайті. Status updated: 2026-04-27.

plan_id: PLAN-AUTO-CERVICAL-001-V1 | version: 1 | generated: 2026-04-27T10:14:01.586379+00:00
Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.
Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.
This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.